Announced
Financials
Tags
Friendly
Pharmaceuticals
United States
drug discovery
Acquisition
De-SPAC
Domestic
Merger
Majority
Reverse Takeover
Private
Private Equity
Pending
Single Bidder
Synopsis
Calidi Biotherapeutics, a clinical-stage immuno-oncology company, agreed to go public via a SPAC merger with Edoc Acquisition, a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities, in a $449m deal. “We are excited about combining with Edoc to advance our mission of delivering life-saving oncolytic virus therapies with the potential to revolutionize patient care. This business combination positions us well as we enter the next phase of our growth, delivering on the promise of our NeuroNova (NNV) and SuperNova (SNV) platforms, to surpass the deficiencies of the first generation oncolytic viruses existing in the marketplace. Furthermore, it will allow us to leverage Edoc’s extensive 400+ physician network across many disciplines,” Allan Camaisa, Calidi Biotherapeutics CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.